Overview for today. NSG and NSG -SGM3 are a proven platform. A growing list of drugs have shown translationally relevant response

Transcription

1 1

2 Overview for today NSG and NSG -SGM3 are a proven platform A growing list of drugs have shown translationally relevant response Targeted therapeutics and anti-angiogenesis drugs show their expected response Combination studies are beginning now Additional model systems will allow for the interrogation of new targets In Vivo Pharmacology Services 2

3 Key Elements Extensive humanized model experience. >Six years of experience in humanized mice. >20,000 mice engrafted >4,000 PDX engrafted humanized mice run on study 7 checkpoint inhibitors used Extensive experience with CD34+ and custom stem cells Large repository of genomically-characterized tumors, Full access to genomic for data humanization. and tissue samples for target confirmation, Advanced humanized evaluate models therapies. produced at industrial scale, NSG-PDX Library of >400 models Heme-Onc PDX Library Expert In Vivo study team who pioneered the use of Humanized Mice (IO, Immunology) humanized models for IO Public compound Access Genomic validation, Database and A dedicated scientific partner. Biomarker Samples INNOVATIVE PRECLINICAL PLATFORMS FOR IMMUNO- ONCOLOGY A suite of human tumor and immune system models to Inventory of humanized mouse models available for immediate shipment or study enrollment. Hu-NSG-CD34+ Hu-SGM3-CD34+ Hu-PBMC Additional NSG variants available for custom engraftment projects 3

4 Onco-Hu Humanized Mice for Evaluation of Immuno-Oncology Therapeutics Characteristics of humanized NSG & NSG - SGM3 mice Targets & tumor types Non-IO compound in Hu-Mice Combinations New models In Vivo Pharmacology Services 4

5 NSG and NSG -SGM3 Mice NOD scid gamma (NSG) NOD.Cg-Prkdc scid Il2rg tm1wjl /SzJ (005557) The current gold standard for reconstitution of the human immune system Excellent functional T cell responses Limited human myeloid lineage development NSG-SGM3 NOD.Cg-Prkdc scid Il2rg tm1wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ (013062) Promotes improved AML engraftment efficiency Improves normal human myeloid cell development after HSC transplantation Wunderlich M. et al Leukemia 24(10): PMID: Billerbeck E. et al Blood 117(11): PMID:

6 Human Immune Cells in Peripheral Blood of Hu-NSG and Hu-NSG -SGM3: Absolute Counts Total Human Donor (cells/µl) Human Myeloid Cells (cells/µl) In Vivo Pharmacology Services 6

7 Human Immune Cells in Peripheral Blood of Hu-NSG and Hu-NSG -SGM3: Absolute Counts Helper T Cells (cells/µl) Cytotoxic T Cells (cells/µl) In Vivo Pharmacology Services 7

8 Onco-Hu Humanized Mice for Evaluation of Immuno-Oncology Therapeutics Characteristics of humanized NSG & NSG -SGM3 mice Targets & tumor types Non-IO compound in Hu-Mice Combinations New models In Vivo Pharmacology Services 8

9 Selecting a PDX model that has been well characterized in Hu-Mice is important for your study Model Primary Site Validated Growth PD-L1+ (%) Keytruda Tested in Hu-mice Growth Rates TM00302 Lung Hu-NSG & Hu-SGM Responder (hu-nsg and Hu-SGM3) Regular (Easy Ulceration) TM00098 Breast Hu-NSG & Hu-SGM Responder (hunsg, hu-sgm3) Regular J Skin Hu-NSG & Hu-SGM Responder (hunsg, hu-sgm3) Regular TM00199 Lung Hu-NSG 6.4 Responder (hu-nsg) Very Slow TM00016 Bladder Hu-NSG Responder (hu-nsg) Fast TM00231 Lung Hu-NSG & Hu-SGM3 7.4 Responder (hu-nsg) Regular TM00702 Skin Hu-NSG & Hu-SGM Grower, Non-Responder (hu-nsg) Standard TM00943 Skin Hu-NSG & Hu-SGM Grower, Non-Responder (hu-nsg) Standard TM00233 Lung Hu-NSG 13.5 Grower, Non-Responder (hu-nsg) Slow TM00165 Anal Hu-NSG 36 Grower, Non-Responder (hu-nsg) Slow TM00292 Lung Hu-NSG Grower, Non-Responder (hu-nsg) Slow TM00381 Soft tissue Hu-NSG & Hu-SGM Grower, Non-Responder (hu-nsg) Regular TM00212 Lung Hu-NSG 12.3 Grower, Non-Responder (hu-nsg) Very Slow TM00784 Lung Hu-NSG 42.5 Grower, Non-Responder Fast TM00282 Skin Hu-SGM Fast TM00170 Colon Hu-NSG 12.9 Regular TM00090 Breast Hu-NSG Fast TM00024 Bladder Hu-NSG 13.4 Fast TM00213 Lung Hu-NSG 10.9 Very Slow Fast Grower (3-5 Weeks) Regular Grower (4-6 Weeks) Slow Grower (8-10 Weeks) Very Slow Grower (>3 Months)

10 Human CD45+ and CD33+ infiltration into PDX tumors in Hu-NSG-SGM3 mice PDX model %hcd45+ % CD33+ of CD45+ cells BR1126 (TNB) ~15 J99327 (TNB) LG1306 (Lung) H460 cell line (Lung) SK1260 (Melanoma) MDA-MB-231 (TNB cell line) ~20 ~5 CN1572 (Colon) ~3 ~13 (mdcs), (TAMs) SA0209 (Sarcoma) J (Melanoma) , (TAMs) TM1149 (Melanoma) , 3-9 (TAMs) In Vivo Pharmacology Services 10

11 Characterization of infiltrating T Cell in melanoma PDX grown in Hu-SGM3 T cells in Onco-Hu-SGM3 Melanoma Markers Levels CD3T CD3+ 20% of CD45+ Treg CD25high D127 lowfoxp3+ 5% of CD45+ Exhausted CD4T PD1+ CD4+ 10% of CD4+ Exhausted CD8T PD1+ CD8+ 55% of CD8+ Naïve CD8T CCR7+CD45RA+CD8+ 3% of CD8+ Central memory CD8T CCR7+CD45RA-CD8+ 2% of CD8+ Effector memory CD8T CCR7-CD45RA- CD8+ 95% of CD8+ Naïve CD4T CCR7+CD45RA+CD4+ 74% of CD4+ Central memory CD4T CCR7+CD45RA-CD4+ 1% of CD4+ Effector memory CD4T CCR7-CD45RA- CD4+ 25% of CD4+ In Vivo Pharmacology Services 11

12 PD-1 in Hu-NSG Suppression of Growth by Pembrolizumab 8

13 PD-1 in Hu-NSG Pembrolizumab initiates CD8 + T Cell infiltration Vehicle Pembrolizumab DAPI CD8 13

14 PD-1 in Hu-NSG Different PD-1 inhibitors Nivolumab and Pembrolizumab matched efficacy 14

15 PD-1 in Hu-SGM3 Similar response seen in Hu-NSG In Vivo Pharmacology Services 15

16 PD-1 in Hu-SGM3 TNBC PDX tumor response similar to cell lines In Vivo Pharmacology Services 16

17 CTLA-4 in Hu-NSG -SGM3 Suppression of lung PDX tumor growth In Vivo Pharmacology Services 17

18 PD-L1 (Avelumab) in Hu-NSG Suppression of tumor growth in TNBC cell line MDA_MB-231 Mean Tumor Volume (3 donors) 18

19 M e a n T u m o r V o l u m e ( m m 3 ) + / - S E M OX40 in Hu-NSG Suppression of TNBC cell line tumor growth T w o D o n o r s ( # , # ) * * G r o u p 1 ( V e h i c l e ) G r o u p 3 ( a n t i - O X 4 0 ) * * * * * * p < * * p < * * * p < * * * * p < * 2 - t a i l e d u n p a i r e d t - t e s t S t u d y D a y s Jean Gudas VP, Research & Development ImaginAb, Inc. 19

20 IDO in Hu-NSG Suppression of TNBC cell line tumor growth MDA-MB-231 Mean Tumor Volume (3 donors) 20

21 Onco-Hu : Humanized Mice for Evaluation of Immuno-Oncology Therapeutics Characteristics of humanized NSG and NSG - SGM3 mice Targets & tumor types Non-IO compounds in Hu-Mice Combinations New models In Vivo Pharmacology Services 21

22 DLL4 (angiogenesis) Hu-NSG -SGM3 Inhibits Tumor Growth in NSCLC PDX model OMP-LU121 NSCLC did not respond to Pembrolizumab in Hu-NSG-SGM3 mice Demcizumab (21MR) alone suppressed progression of tumor growth *p MR ± PD1 vs Control, D11 **p MR ± PD1 vs Control, D19 Chris Murriel & Tim Hoey OncoMed Pharmaceuticals 22

23 DNA Damage - Hu-SGM3 Expected Doxorubicin response in TNBC PDX In Vivo Pharmacology Services 23

24 Onco-Hu : Humanized Mice for Evaluation of Immuno-Oncology Therapeutics Characteristics of humanized NSG and NSG - SGM3 mice Targets & tumor types Non-IO compounds in Hu-Mice Combinations New models 24

25 IDO & PD-L1 - Hu-NSG TNBC cell line response suggestive of synergy Additional validation is needed 25

26 Onco-Hu : Humanized Mice for Evaluation of Immuno-Oncology Therapeutics Characteristics of humanized NSG and NSG - SGM3 mice Targets & tumor types Non-IO compound in Hu-Mice Combinations New models In Vivo Pharmacology Services 26

27 Humanized models will continue to rapidly develop and JAX has a number of new models coming soon Hu-NSG-HLA.A2 o Engraft mice with HLA-A2 CD34 cells and tumors for Class I autologous Immuno-oncology studies PBMC humanization with PDX/CDX immunooncology Hu-NSG-NK model and many more. In Vivo Pharmacology Services 27

28 Immuno-Oncology Summary NSG and NSG -SGM3 are a proven platform for engraftment of the human immune system A growing list of drugs have shown translationally relevant response in the humanized mouse system. Target Therapeutics and anti-angiogenesis drugs show their expected response Combination studies are underway and new data is coming soon. Additional model systems will allow for the interrogation of new targets In Vivo Pharmacology Services 28

29 Acknowledgements JAX In Vivo Pharmacology Services o James Keck o Minan Wang o Li-Chin Yao o Mingshan Cheng o Danying Cai JAX Genomic Medicine o Karolina Palucka JAX Mammalian Genetics o Lenny Shultz o Brian Soper o Carol Bult o Susie Airhart o Ed Liu UMASS o Dale Greiner and Mike Brehm 29

30 12-16 wks 30